J2371 HCPCS code: Injection, phenylephrine hydrochloride, 20 micrograms
J2371 is the HCPCS Level II code for injection, phenylephrine hydrochloride, 20 micrograms. In 2024 Medicare paid an average of $0.19 per service for J2371 across 7,901 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. Medicare volume rose 812% from 2023 to 2024 (866 to 7,901 services). In 2024, about 43 clinicians billed Medicare for J2371 for 119 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2023-07-01 |
| Last action effective | 2023-07-01 |
Who bills J2371 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 43 |
| Medicare beneficiaries | 119 |
| States with claims | 4 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J2371, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 866 | 74 | $0.33 | $0.27 |
| 2024 | 7,901 | 119 | $0.23 | $0.19 |
States with the most J2371 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Minnesota | 1,575 | $0.11 |
| Florida | 707 | $0.01 |
| Virginia | 35 | $0.01 |
| Oklahoma | 13 | $0.01 |
What changed for J2371
- 2023-07-01: J2371 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2371?
J2371 is the HCPCS Level II code for injection, phenylephrine hydrochloride, 20 micrograms. Short descriptor: "Inj phenylephrine hcl 20 mcg".
How much does Medicare pay for J2371?
In 2024, the average Medicare payment was $0.19 per service (average allowed $0.23).
Does Medicare cover J2371?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related J23 codes
- J2300 — Injection, nalbuphine hydrochloride, per 10 mg
- J2305 — Injection, nitroglycerin, 5 mg
- J2310 — Injection, naloxone hydrochloride, per 1 mg
- J2311 — Injection, naloxone hydrochloride (zimhi), 1 mg
- J2312 — Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313 — Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315 — Injection, naltrexone, depot form, 1 mg
- J2320 — Injection, nandrolone decanoate, up to 50 mg
- J2323 — Injection, natalizumab, 1 mg
- J2325 — Injection, nesiritide, 0.1 mg
- J2326 — Injection, nusinersen, 0.1 mg
- J2327 — Injection, risankizumab-rzaa, intravenous, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2371
- Watch J2371 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2371
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.